Clinical Trial Update: Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma [NA]

View source ↗

Summary

ClinicalTrials.gov reports a completed frontline trial comparing Brentuximab Vedotin with AVD versus ABVD chemotherapy in patients with advanced classical Hodgk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Sponsor: Helwan University | Conditions: Anti-CD30, Brentuximab | NA | Status: COMPLETED